Agios Pharmaceuticals (NASDAQ:AGIO) Reaches New 52-Week Low – What’s Next?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares hit a new 52-week low during mid-day trading on Friday . The stock traded as low as $26.03 and last traded at $26.54, with a volume of 86040 shares traded. The stock had previously closed at $27.71.

Analysts Set New Price Targets

Several research firms have weighed in on AGIO. StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They issued a “buy” rating and a $58.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Scotiabank raised their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. Finally, Royal Bank of Canada upped their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $56.57.

Agios Pharmaceuticals Trading Down 7.0 %

The firm has a 50-day moving average of $32.55 and a 200 day moving average of $40.23. The stock has a market capitalization of $1.48 billion, a price-to-earnings ratio of 2.27 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Equities research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now owns 18,906 shares in the company, valued at $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.93% of the stock is owned by insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Venturi Wealth Management LLC bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth $33,000. GF Fund Management CO. LTD. bought a new stake in Agios Pharmaceuticals in the fourth quarter worth about $39,000. Wingate Wealth Advisors Inc. acquired a new stake in Agios Pharmaceuticals in the 4th quarter valued at about $53,000. Sterling Capital Management LLC boosted its position in shares of Agios Pharmaceuticals by 818.0% during the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 1,587 shares in the last quarter. Finally, KBC Group NV lifted its stake in Agios Pharmaceuticals by 30.5% during the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 611 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.